Clinical trials have demonstrated that IL-15 can significantly improve the persistence and effectiveness of CAR NK cells in targeting CD19-positive lymphoid tumors, offering new hope for patients with certain types of cancer [175]. This evidence concerns the gene IL15 and cancer.